Insulet Corporation is a medical devices business based in the US. Insulet Corporation shares (PODD) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $258.79 – an increase of 2.99% over the previous week. Insulet Corporation employs 3,900 staff and has a trailing 12-month revenue of around $2.1 billion.
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $258.79 |
|---|---|
| 52-week range | $160.19 - $289.46 |
| 50-day moving average | $260.87 |
| 200-day moving average | $244.97 |
| Wall St. target price | $313.60 |
| PE ratio | 43.6488 |
| Dividend yield | N/A |
| Earnings per share (TTM) | $5.78 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $257.01 from 2025-05-02
| 1 week (2025-04-28) | -0.97% |
|---|---|
| 1 month (2025-04-04) | 4.79% |
| 3 months (2025-02-06) | -10.66% |
| 6 months (2024-11-06) | 7.40% |
| 1 year (2024-05-06) | 45.70% |
|---|---|
| 2 years (2023-05-05) | -21.82% |
| 3 years (2022-05-05) | 13.27% |
| 5 years (2020-05-05) | 27.70% |
Valuing Insulet Corporation stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Insulet Corporation's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Insulet Corporation's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 44x. In other words, Insulet Corporation shares trade at around 44x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Insulet Corporation's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 6.4022. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Insulet Corporation's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Insulet Corporation's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $389.7 million.
The EBITDA is a measure of a Insulet Corporation's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $2.1 billion |
|---|---|
| Operating margin TTM | 16.03% |
| Gross profit TTM | $1.4 billion |
| Return on assets TTM | 6.8% |
| Return on equity TTM | 43.03% |
| Profit margin | 20.19% |
| Book value | $17.26 |
| Market Capitalization | $17.7 billion |
TTM: trailing 12 months
We're not expecting Insulet Corporation to pay a dividend over the next 12 months.
Over the last 12 months, Insulet Corporation's shares have ranged in value from as little as $160.19 up to $289.46. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Insulet Corporation's is 1.303. This would suggest that Insulet Corporation's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; and Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts. .
Some of the best paper trading apps to practice stock trading with fake money include Interactive Brokers, eToro, Charles Schwab and more.
These are the stocks to buy when you don’t have much to spend.
These are the best day trading apps, according to Finder’s comprehensive analysis.
Explore the best bonuses for opening a new brokerage account.
Some of the best stock trading apps for beginners include SoFi, Robinhood, Public, Stash, Opto and more. Compare your options here.
Want to buy and sell international stocks? Here are the top brokers to help you trade global markets.
These are the best discount brokers of 2025 according to Finder’s comprehensive review.
Compare the 7 best stock picking services, according to Finder’s analysis, and learn how to choose the best option for your needs.
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .